Inhibition of angiotensin I-converting enzyme induces radioprotection by preserving murine hematopoietic short-term reconstituting cells

被引:57
作者
Charrier, S
Michaud, A
Badaoui, S
Giroux, S
Ezan, E
Sainteny, F
Corvol, P
Vainchenker, W
机构
[1] Inst Gustave Roussy, INSERM, U362, F-94805 Villejuif, France
[2] Coll France, INSERM, F-75231 Paris, France
[3] CEA Saclay, Gif Sur Yvette, France
关键词
D O I
10.1182/blood-2003-11-3828
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Angiotensin I-converting enzyme (ACE) inhibitors can affect hematopoiesis by several mechanisms including inhibition of angiotensin II formation and increasing plasma concentrations of AcSDKP (acetyl-N-Ser-Asp-Lys-Pro), an ACE substrate and a negative regulator of hematopoiesis. We tested whether ACE inhibition could decrease the hematopoietic toxicity of lethal or sublethal irradiation protocols. In all cases, short treatment with the ACE inhibitor perindopril protected against irradiation-induced death. ACE inhibition accelerated hematopoietic recovery and led to a significant increase in platelet and red cell counts. Pretreatment with perindopril increased bone marrow cellularity and the number of hematopoietic progenitors (granulocyte macrophage colony-forming unit [CFU-GM], erythroid burst-forming unit [BFU-E], and megakaryocyte colony-forming unit [CFU-MK]) from day 7 to 28 after irradiation. Perindopril also increased the number of hematopoietic stem cells with at least a short-term reconstitutive activity in animals that recovered from irradiation. To determine the mechanism of action involved, we evaluated the effects of increasing AcSDKP plasma concentrations and of an angiotensin II type 1 (AT1) receptor antagonist (telmisartan) on radioprotection. We found that the AT1-receptor antagonism mediated similar radioprotection as the ACE inhibitor. These results suggest that ACE inhibitors and AT1-receptor antagonists could be used to decrease the hematopoietic toxicity of irradiation. (C) 2004 by The American Society of Hematology.
引用
收藏
页码:978 / 985
页数:8
相关论文
共 34 条
[1]  
Aidoudi S, 1998, INT J HEMATOL, V68, P145
[2]   High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline - A new marker of chronic angiotensin-converting enzyme inhibition [J].
Azizi, M ;
Ezan, E ;
Nicolet, L ;
Grognet, JM ;
Menard, J .
HYPERTENSION, 1997, 30 (05) :1015-1019
[3]   Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline [J].
Azizi, M ;
Rousseau, A ;
Ezan, E ;
Guyene, TT ;
Michelet, S ;
Grognet, JM ;
Lenfant, M ;
Corvol, P ;
Menard, J .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (03) :839-844
[4]  
BONNET D, 1995, EXP HEMATOL, V23, P551
[5]   Captopril inhibits the proliferation of hematopoietic stem and progenitor cells in murine long-term bone marrow cultures [J].
Chisi, JE ;
Wdzieczak-Bakala, J ;
Thierry, J ;
Briscoe, CV ;
Riches, AC .
STEM CELLS, 1999, 17 (06) :339-344
[6]   Captopril inhibits in vitro and in vivo the proliferation of primitive haematopoietic cells induced into cell cycle by cytotoxic drug administration or irradiation but has no effect on myeloid leukaemia cell proliferation [J].
Chisi, JE ;
Briscoe, CV ;
Ezan, E ;
Genet, R ;
Riches, AC ;
Wdzieczak-Bakala, J .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 109 (03) :563-570
[7]   MOLECULAR MECHANISMS OF VASCULAR RENIN-ANGIOTENSIN SYSTEM IN MYOINTIMAL HYPERPLASIA [J].
DZAU, VJ ;
GIBBONS, GH ;
PRATT, RE .
HYPERTENSION, 1991, 18 (04) :100-105
[8]  
EZAN E, 1994, DRUG METAB DISPOS, V22, P843
[9]  
Fortunel NO, 2000, BLOOD, V96, P2022
[10]   The aging of lympho-hematopoietic stem cells [J].
Geiger, H ;
Van Zant, G .
NATURE IMMUNOLOGY, 2002, 3 (04) :329-333